Mycoplasma Conference Guide 2014 PDA Europe
Transcription
Mycoplasma Conference Guide 2014 PDA Europe
The Parenteral Drug Association presents... 2014 PDA Europe Mycoplasma Current and Emerging Practices in Industrial Mycoplasmology Including the new 2014 PDA Technical Report on Mycoplasma Filtration 1 October 2014 Training Course Introduction to Mycoplasma Filtration 29-30 September 2014 Hotel Courtyard Berlin Mitte Berlin | Germany Cou r tes y o f Re n a t e R o s e ng ar te n Premium Sponsor: CONFERENCE 29-30 Sept | EXHIBITION 29-30 Sept | TRAINING COURSE 1 Oct Conference Guide Welcome from the Chair With this year's focus on Industrial Mycoplasmology, we warmly welcome you to Berlin! We are happy to once again offer you a highly informative and educational forum, highlighting current mycoplasma methods, concepts and regulation. Mycoplasma contamination in biopharmaceutical products causes significant financial loss, yet information about these contamination events is rarely shared and little is known about the issue overall. This workshop aims to encourage transparency, to share and discuss the challenges we face, and work together in identifying appropriate methods and tools that prevent mycoplasma-contaminated products. Several industry representatives will present how they won approval from the FDA CDER, CBER, and the EMA for using NAT methods to detect mycoplasmas in biopharmaceutical products, and a regulatory representative of the German Paul-Ehrlich-Institute will outline how the WHO International Standard (IS) for mycoplasma NAT was developed and approved. A discussion will follow about how the IS can be used in validation studies using NAT methods. Specifically, mycoplasma filtration will be discussed in detail, both from a regulatory and vendor perspective. Regulatory speakers from FDA and EDQM will provide information about what is required for mycoplasma filtration validation or verification, and an update about the EDQM mycoplasma reference preparations recommended in the EP guidance for mycoplasma testing by the conventional culture method will be given. A user perspective and other emerging mycoplasma filtration technologies from multiple filter manufacturers will be preceded by a presentation about a new publication on a consensus method for mycoplasma filtration, the PDA Mycoplasma Filtration Technical Report. In addition, raw material manufacturers for peptones and sera will share how they reduce the risk of mycoplasma contamination in their products. Finally, mycoplasma experts will address hot topics that include emerging mycoplasma issues relevant for mycoplasma detection, prevention and control that may also be important in the field of Advanced Therapy Medicinal Products. New data will be presented about “non-cultivable” mycoplasmas such as hemoplasmas, phytoplasmas and cultivar α strains, and how to detect them. The conference will be complemented by a poster session, a vendor exhibition, and a Training Course on Mycoplasma Filtration, with leading experts in the field sharing their insights, methods and technological advances. We have compiled a program that will provide you with the latest information on Mycoplasma, and we look forward to a fruitful meeting and many exciting discussions on this highly specialized topic. Welcome! Barbara J. Potts, Ph.D. Chair, Potts & Nelson Consulting Information PDA Contact Event Registration Antje Petzholdt Registration & Membership Management [email protected] Membership Management Interest Group General Event Information Call for Papers Sylvia Becker Program Coordinator [email protected] Presentations Speaker Biographies Event Agenda Committee Information Creixell Espilla-Gilart Exhibition & Sponsorship Management [email protected] Exhibition Information Sponsoring Opportunities Scientific Planning Committee Barbara Potts, Chair, Potts and Nelson Consulting Thomas Hämmerle, Baxter Gerhard Haake, Sartorius-Stedim Biotech Micha Nübling, Paul-Ehrlich-Institute Renate Rosengarten, Mycoplasma Biosafety Services Georg Roessling, PDA Europe Sylvia Becker, PDA Europe Venue Courtyard Berlin Mitte Axel-Springer-Straße 55 10117 Berlin Germany Tel.: +49 (0) 30 800 928 0 Fax: 49-30-8009281000 www.marriott.de/hotels/travel/bermt-courtyard-berlincity-center/ Keyvisual on Title Special Thanks to Prof. Renate Rosengarten, DVM, Ph.D. Mycoplasma Biosafety Services GmbH BioTech Center Muthgasse | Muthgasse 11/2 1190 Vienna | Austria 2014 PDA Europe Parenterals 18-19 February 2014 Berlin | Germany 4-5 November 2014 Munich | Germany CONFERENCE 4-5 Nov | EXHIBITION 4-5 Nov | TRAINING COURSES 6-7 Nov europe.pda.org/Parenterals2014 https://europe.pda.org/Myco2014 3 Agenda Monday, 29 September 2014 9:00 Welcome and Introduction Session 1: Regulatory Update Georg Roessling, PDA Europe Barbara Potts, Conference Chair Moderator: Oliver Karo Regulatory expectations for safety and efficacy of biological medicines include a thorough characterization of laboratory methods applied. The validation of methods for the detection of contaminants is an important prerequisite for their acceptance. International reference preparations facilitate the comparability of validation exercises. The new WHO International Standard for Mycoplasma DNA will support the comparative characterization of nucleic acid amplification techniques of generic design applied for detection of mycoplasma contaminations. 9:15 Method Validation Vinayak Pawar, FDA 9:45 WHO International Standard Micha Nübling, Paul-Ehrlich-Institute 10:15 Mycoplasma Testing in the European Pharmacopoeia Catherine Milne, EDQM 10:45 Q & A, Panel Discussion with Regulators 11:15 Coffee Break & Exhibition 11:45 Anonymous Audience Survey & Discussion: Industry Practices Regarding Mycoplasma Control Session 2: PDA Technical Report on Mycoplasma Filtration Barbara Potts, Consultant Christine Wright, EMD Millipore Moderator: Thomas Hämmerle PDA publishes a series of reports covering topics relevant to the pharmaceutical industry and stakeholders. One of them will be the long awaited PDA Technical Report about Mycoplasma Filtration. There are two presentations giving a preview, starting with an overview about the report, including the challenges regarding filtration of Mycoplasma. 12:30 Preview of the Upcoming Technical Report on Mycoplasma Filtration Barbara Potts, Consultant 13:00 Overview of the Paper Published in the PDA Journal Gerhard Haake, Sartorius-Stedim 13:30 Lunch Break & Exhibition Session 3: Raw Materials Moderator: Barbara Potts Mycoplasma contamination in the Biopharmaceutical industry causes significant financial loss and to date most contaminations are caused by large volume raw materials such as serum or peptones. Speakers during this session will address the controls in place to control mycoplasma contamination and the problems with these controls. Also a speaker will outline how the control of mycoplasma is integrated into the broader control of all adventitious agents in raw materials. 4 14:30 Serum and Safe Use - The Supplier's View 15:00 Panel Discussion 15:30 Coffee Break & Exhibition https://europe.pda.org/Myco2014 Rosemary Versteegen, International Serum Industry Association Agenda Session 4: PCR Assays Moderator: Thomas Hämmerle There is quite a lot of information about PCR based Mycoplasma testing in general. However, there is still little information about the implementation of PCR based Mycoplasma testing for lot release, especially regarding potential pitfalls and issues and means to avoid them. Based on vast knowledge in PCR based Mycoplasma testing regarding technical and regulatory aspects, this session will feature presentations of methods that received FDA and/or EMA approval. 16:00 Nucleic Acid-Based Rapid Detection of Mycoplasma for Lot Release Testing Martina Kopp, Amgen 16:30 Successful mycoTOOL Application to FDA Sven Deutschmann, Roche 17:00 Q&A, Discussion 17:30 End of Day 1 & Networking Reception in the Exhibition Area Tuesday, 30 September 2014 Session 5: Validation of Rapid Mycoplasma Detection Methods Moderator: Barbara Potts A major challenge for Biotechnology companies and for Regulatory Agencies is how to standardize the assays in regard to colony forming units (CFU), genomic copy and CFU/ml when developing NAT methods to detect mycoplasma. An International Standard (IS) has been established by the World Health Organization for NAT detection of mycoplasma to address this significant issue. A representative of the German Paul-Ehrlich-Institute will outline how the WHO IS for mycoplasma NAT was developed and approved. A discussion will follow about how the IS can be used in validation studies using NAT methods. 9:00 WHO IS in Validations Micha Nübling, Paul-Ehrlich-Institute 9:20 User’s Perspective on the WHO IS in Validations Sven Deutschmann, Roche 9:50 Efficient Mycoplasma Concentration Technique for Increasing Real-Time PCR Sensitivity in Large Sample Volumes Dirk Vollenbroich, Minerva Analytix 10:20 Validation Strategies for Real Time qPCR-based Mycoplasma Detection Assays Michael Brewer, Thermo Fisher Scientific 10:50 Q & A, Discussion 11:15 Coffee Break & Exhibition Session 6: Filtration Moderator: Gerhard Haake Mycoplasma contamination in biopharmaceutical products causes significant costs. In the biopharmaceutical industry, an effective filtration of Mycoplasma is needed for large scale mammalian and bacterial cell culture media. In this session, the importance of direct flow filters to reduce the risk of a Mycoplasma contamination will be demonstrated. Important aspects for process qualification of 0.1 µm rated filters will be presented, and a poster session will provide a solid base for discussion and exchange of these topics. 11:45 Cell Culture Media Sterility: Key Considerations when Selecting Direct Flow Mycoplasma Filters Tom Watson, Pall Life Sciences 12:15 Mycoplasma Retentive Filtration: Important Aspects for Process Qualification of 0.1 µm Rated Filters Volkmar Thom, Sartorius-Stedim 12:45 Barrier and Beyond: What Does it Take to Protect the Bioreactor from Virus? Damon R. Asher, EMD Millipore 13:15 Q & A, Discussion 13:45 Lunch Break & Exhibition https://europe.pda.org/Myco2014 5 Agenda Session 7: Hot Topics in Industrial Mycoplasmology Moderator: Renate Rosengarten This Session will review the newest developments in the field of Industrial Mycoplasmology. The two presentations given by mycoplasma experts will particularly address recent advances in the detection, prevention and control of mycoplasmas that are considered “non-cultivable”: the highly fastidious cell culture-adapted cultivar α strains, the haemoplasmas - a novel group of mycoplasmas within the genus Mycoplasma that are found on and in red blood cells - and finally, the phytoplasmas that infect plants and are also found in insects. 14:45 Emerging Issues in Industrial Mycoplasmology – An Overview Renate Rosengarten, Mycoplasma Biosafety Services 15:15 “Non-Cultivable” Mycoplasmas and Their Detection: Haemoplasmas, Phytoplasmas and Cultivar α Strains Helena Windsor, Mycoplasma Experience Session 8: Advanced Therapy Medicinal Products (ATMPs) 15:45 Mycoplasma Control of Advanced Therapy Medicinal Products – A Regulator´s View 16:15 Panel Discussion with Regulators of Sessions 1 and 8 17:00 Closing Comments & Farewell Coffee Moderator: Jill Mariano Oliver Karo, Paul-Ehrlich-Institute Georg Roessling, PDA Europe The Parenteral Drug Association presents... 2014 PDA Europe Outsourcing/ Contract Manufacturing 4 December 2014 One-Day Training Course Managing Outsourced Operations 2-3 December 2014 Hilton Hotel Berlin | Germany CONFERENCE 2-3 Dec | E XHIBI T ION 2-3 Dec | T R AINING COUR SE 4 Dec https://europe.pda.org/Outcon2014 6 https://europe.pda.org/Myco2014 Scientific Planning Committee Members Conference Chair Barbara Potts, Ph.D., Potts & Nelson Consulting Dr. Potts specializes in the control of adventitious agents (viruses, mycoplasma and prions) from a compliance, science and business focus. Her previous experience includes directing scientific and compliance activities for microbiology, raw materials, virology, mycoplasma, potency, environmental monitoring, cell bank testing for adventitious agents, TSE control in raw materials, nucleic acid method development and strategic planning for new technologies for the detection of mycoplasma and viruses. She has work experience with the USDA, ARS, the NIH (NIAID and NINCDS), the University of MN School of Veterinary Medicine and three biotechnology companies. Her Ph.D. research was focused on the characterization of a new virus that caused congenital defects in the CNS of fetal lambs as a model for virus infections in humans. Gerhard Haake, Sartorius Stedim Biotech GmbH Gerhard Haake was born in Lüdenscheid, Germany. He studied at the University of Applied Science in Münster/ Germany and has a degree in Ecotrophology. After his studies, he started working in the Quality Assurance section at Sartorius Stedim Biotech GmbH as a Laboratory Manager of the Microbiological Laboratory. Since 2011, he has been working in the PDA Mycoplasma Filtration Group for the upcoming Mycoplasma Filtration Technical Report. In addition, he is an ISO delegate for water microbiology and a member of some national committees for microbiological issues. Thomas Hämmerle, Ph.D., Baxter Following basic training in Biology and a postdoctoral fellowship at SUNY Stony Brook, Thomas joined Immuno AG, which is now part of Baxter, and is currently heading the Department of Molecularbiological Control at the Baxter site in Orth/ Danube, Austria. Thomas’s expertise relates to the fields of molecular biology, virology, biochemistry and cell biology. Thomas is author and co-author of more than twenty peer reviewed papers, book chapters and patents. He is a member of the EDQM Mycoplasma and CTP working parties, member of the USP Residual DNA working party and co-chair of the PDA Mycoplasma Task Force Testing Subgroup. In addition, Thomas is speaker at numerous conferences dealing with current topics relevant for the biopharmaceutical industry. Micha Nübling, Ph.D., Paul-Ehrlich-Institute Graduating from Freiburg University, Dr. M. Nübling joined the Paul-Ehrlich-Institute (PEI) as Molecular Biologist in the 90s. He started at PEI with the testing and approval of in-vitro diagnostics (IVD) in Germany. Later, as head of the “Molecular Virology” department, M. Nübling focused on the evaluation of nucleic acid amplifications techniques (NAT) for the safety testing of biologicals. In this role, he performed several research projects and also joined the WHO Collaborating Center for IVD, leading several WHO standardization projects. He was involved in the introduction of NAT testing for blood products in Germany and Europe and is a member of several EMA and EDQM working groups. Renate Rosengarten, Ph.D., Mycoplasma Biosafety Services Renate Rosengarten’s academic career has been marked by a continuous interest in the infection biology of mycoplasmas for more than 35 years. Her passion for mycoplasmas took her to the School of Veterinary Medicine Hannover, the University of Missouri-Columbia and the Hadassah Medical School of the Hebrew University in Jerusalem. Since 1996, Renate Rosengarten has been Professor of Bacteriology and Hygiene at the University of Veterinary Medicine Vienna in Austria. She was head of the Institute of Bacteriology, Mycology and Hygiene for more than 17 years, was founder and managing director of the former Mycosafe Diagnostics GmbH, and is currently CSO and COO of the newly established biosafety company Mycoplasma Biosafety Services GmbH which was founded in December 2013 at her initiative and with her support. Renate Rosengarten is author of over 100 publications on mycoplasmas in peer-reviewed scientific journals and books. https://europe.pda.org/Myco2014 7 Speaker / Moderator Biographies Damon R. Asher, Ph.D., EMD Millipore Damon Asher is currently engaged in numerous biosafety and process monitoring initiatives, including novel viral and bacterial clearance and detection technologies. He is the lead scientist for EMD Millipore’s project to develop highly purified virus preparations for use in virus spiking studies, and has served as an author of PDA technical reports on virus spike preparation and virus filtration. He is currently focused on the creation of integrated solutions for protection of the bioreactor from viral and bacterial contamination. Damon holds a Ph.D. in Immunology from Harvard University and a Master’s Degree in Biomedical Sciences from Harvard Medical School. Michael Brewer, Thermo Fisher Scientific Michael Brewer is the Head of Pharmaceutical Analytics at Thermo Fisher Scientific, leading the team responsible for product applications including Microbiology, Analytical Sciences and Quality control. The products are fully integrated, molecular solutions for Bacterial and Fungal identification, Mycoplasma and Viral detection and host cell DNA and protein quantitation. Michael has over 30 years’ experience in the Biopharma industry, including, Scios, Synergen and Amgen in a variety of roles including Discovery Research, Analytical Sciences and Quality Control. Prior to joining Thermo Fisher Scientific, he lead a group at Amgen that developed qualified, validated and implemented molecular methods for host cell DNA quantitation, contaminant (Mycoplasma, Virus and Bacteria) detection, contaminant identification, strain typing and genotypic verification of production cell lines. Sven Deutschmann, Roche Sven M. Deutschmann studied biology (major: microbiology, biochemistry and biotechnology) at the University of Brunswick where he obtained his Ph.D. in cell culture technology. In 1995 he joined Roche Diagnostics GmbH as Manager QC. In the past years he took over increasing local and global responsibilities and accountabilities within the Roche / Genentech Biologics QC Network as well as in the field of External Interaction. Currently, Sven Deutschmann is responsible for the microbiological, molecular and cell biological analytics of QC- and In-Process-Control-samples in the production of biotechnological derived commercial and clinical active pharmaceutical ingredients. Beginning of 2012 he was appointed as Global Head of a Corporate Function called “Method Management and Technology” within the Biologics Operational Unit of Roche / Genentech with special focus on PCR- / NAT-based technologies and Rapid Microbiological Methods. In addition, he is member of the PDA “Mycoplasma Task Force” and chairman of the Advisory Board of the ECA “Rapid Microbiological Methods Working Group”. Oliver Karo, Paul-Ehrlich-Institute Oliver studied Biology at the Technical University in Darmstadt with focus on Microbiology. Since 2009, he has been working at the Paul-Ehrlich-Institute in the Division Microbial Safety. He is a quality assessor and a national expert advisor for the microbial safety of advanced therapy medicinal products (ATMPs) and member of the “Cell Therapy Products” Working Party of the German Pharmacopoeia Commission. Martina Kopp, Ph.D., Amgen Martina Kopp received her Ph.D. in molecular virology from the Friedrich-Löffler-Institut, the Federal Research Institute for Animal Health in Germany, in 2004. She continued her work in the virology field by completing a post-doctoral fellowship at the Center of Hepatitis C Research at the Rockefeller University in New York. Martina Kopp joined the Biosafety Development Group at Amgen in 2011 where she focuses on the risk mitigation of adventitious contaminations in manufacturing processes, the detection and identification of such contaminants as well as the viral clearance assessment for products produced in mammalian cell culture. 8 https://europe.pda.org/Myco2014 Speaker / Moderator Biographies Jill Mariano, MD., Vice President, Bionique Testing Laboratories Jill Mariano, MD, received her Doctor of Medicine degree from Hahnemann University School of Medicine in Philadelphia, PA. She joined Bionique in 2008. In the capacity of Vice President, she is in charge of leading collaborative efforts in the development and implementation of Bionique’s overall strategic plan. Dr. Mariano is currently a member of the PDA Mycoplasma Task Force and served on the subcommittee of Alternative Methods for Mycoplasma Testing. Catherine Milne, Ph.D., EDQM Catherine Milne received her Ph.D. from the University of Toronto, Department of Molecular and Medical Genetics in 1994. From 1994 to 1999 she was a post-doctoral fellow at the Medical Research Council, Laboratory of Molecular Biology in Cambridge, England. In 1999 she joined the Council of Europe, European Directorate for the Quality of Medicines and HealthCare (EDQM), where she is the scientific officer responsible for the Networks of Official Medicines Control Laboratories (OMCLs) involved in Official Control Authority Batch Release (OCABR) of human vaccines, medicinal products derived from human blood and plasma, and veterinary vaccines respectively. She is also involved in the EDQM Biological Standardisation Programme (BSP) and has coordinated a number of projects for the standardisation of methods and reference materials for the evaluation of biologicals in that context. BSP projects have included the establishment of Ph Eur reference preparations for mycoplasma and method and reference development for various human and veterinary vaccines and medicinal products derived from human blood and plasma. Vinayak Pawar, Ph.D., FDA Vinayak is a Senior Regulatory Review Microbiologist with the Office of Pharmaceutical Sciences, CDER, FDA where he serves as a Regulatory, Scientific and Technical consultant providing guidance to industry regarding CDER & CBER cGMP issues and performs risk based quality assessment of the manufacturing and control information submitted in IND, NDA, DMF and post-approval NDA supplements. He serves on FDA Guidance and Technical Committees and trains Pharmaceutical Inspectorate Candidates when required. He received post baccalaureate Medical Technology training and certification at St. Francis Hospital in Peoria, IL and a Master’s Degree in Food Technology from the University of Missouri, Columbia, MI. He earned a Ph.D. degree in Microbiology from University of Kentucky, Lexington, KY. Previously, as a Senior Director at Parkedale Pharmaceuticals & BioReliance Inc. he directed day-to-day QA/QC operations and regulatory affairs while enforcing company-wide cGMP compliance for aseptic filling operations. Prior to serving in the pharmaceutical industry he was the Chairman of the Clinical Laboratory Sciences Department at University of Nevada and the Director of Graduate Medical Technology Program at University of Maryland, School of Medicine. While at FDA he has served on PDA TR 26 Task Force Committee (2008) and currently serves on PDA Mycoplasma Filtration TR Task Force Committee and the PDA Mycoplasma Task Force Filtration Subcommittee. Volkmar Thom, Ph.D., Sartorius-Stedim Volkmar Thom is a Process Engineer by training and received his Ph.D. in Chemical Engineering from the Technical University of Denmark in the area of Membrane Science. After his Post Doc at the Risǿ National Laboratory in Denmark, he switched to industry and held several positions as a membrane scientist at Millipore Corp., since 2003 at Sartorius Stedim Biotech GmbH. Since 2006, he and his R&D group have been responsible for the development and implementation of all synthetic membranes and their respective surface modification at Sartorius Stedim Biotech. https://europe.pda.org/Myco2014 9 Speaker / Moderator Biographies Rosemary Versteegen, Ph.D., International Serum Industry Association Dr. Versteegen received her B.Sc. and Ph.D. degrees in Biochemistry from Glasgow University, Scotland. She held Postdoctoral scholarships at Cambridge University, England and the National Institutes of Health working in areas of disease research. Following several years in NIH sponsored cancer research programs, she joined Life Technologies and held various key roles, both technical and business oriented, including Vice President of the GIBCO Manufacturing Facility, Vice President of Regulatory Affairs, Vice President of New Business Development and Vice President of Strategic Planning. In 2000, Dr Versteegen became a founding partner of the Lifia Group, a consulting organization focused on helping life science and biotechnology companies grow through clearly enunciated, actionable strategic plans. Since its inception in 2006, Dr. Versteegen has been the CEO of the International Serum Industry Association, a global life science notfor-profit association. The mission of the association is to establish, promote and assure compliance with uncompromised standards of excellence and ethics in the business practices of the global animal serum and animal derived products supply industry. The primary focus is on safety and safe use of serum and animal derived products through proper origin traceability, truth in labelling, and appropriate standardization and oversight. Dirk Vollenbroich, Ph.D., Minerva Analytix Dirk Vollenbroich started his career as an engineer for biotechnology with a research focus on peptide antibiotic pathways at the University of Applied Sciences (Berlin, Germany) and acquired a doctorate in biochemistry from the Technical University of Berlin (Germany) for the discovery of novel antibiotic properties of secondary metabolites. At the German Federal Institute for Health, he gained invaluable experience within the field of virus safety of blood products, virus inactivation in biopharmaceutical processes and mycoplasma contamination control of cell-culture-derived materials. Molecular diagnostics and bacterial genomics were of primary interest during his research work at the Louisiana State University Medical Center (USA). In 1999, he founded Minerva Biolabs GmbH, providing products and services for safety and pathogen detection to biopharmaceutical companies and research facilities worldwide. In 2013, he supervised the service department outsourced to Minerva Analytix GmbH and became senior adviser of the company in 2014. Tom Watson, Pall Life Sciences Tom joined Pall in 2003, having graduated from the University of Sheffield, UK with a degree in Biotechnology and Microbiology. Following several years as an Account Manager, in 2010 he joined the Global Product Marketing team to take up his current position as Global Product Manager, Sterilizing-grade Filters. Working closely with Pall R&D, Tom’s key focus is the development and introduction of sterilizing-grade filter products designed for use in biopharmaceutical manufacturing. Helena Windsor, Mycoplasma Experience Helena joined the Wellcome Research laboratories in Beckenham UK from school in 1972 and gained a degree in Applied Biology in 1979. From 1974 to 1985 she worked in the Mycoplasma Section at Wellcome, testing vaccines and cell cultures and assisting in the development of media to grow fastidious strains and species, including the cultivar alpha strains of M.hyorhinis. Mycoplasma Experience was established in 1988 by David and Helena to offer a range of services in mycoplasmology. Helena has taken over the running of the company from David and continues to promote mollicute culture. Research at Mycoplasma Experience focuses on the continuing effort to culture the “unculturable”. Christine Wright, Ph.D., EMD Millipore Christine Wright received her Ph.D. in Microbiology from the University of New Hampshire. She is currently a Research Scientist with EMD Millipore focused on sterilizing filtration validation, single use systems validation and integrity testing for sterile filtration, single-use systems and sterile connectors. 10 https://europe.pda.org/Myco2014 One-Day Training Course Introduction to Mycoplasma Filtration Moderator: Martha Folmsbee, Pall Life Sciences Course Objectives The objectives of the training are to educate filter users about how filters are evaluated, what their risks are with regards to mycoplasma contamination and what filtration can do for them as a mycoplasma control step. Attendees will learn about sterile filtration, how sterile filters are rated and evaluated, and how to apply that knowledge to mycoplasma and mycoplasma filtration as a part of the contamination control routine. Wednesday, 1 October 2014 9:00 -17:00 9:00 Welcome and Introduction Georg Roessling, PDA Europe 9:15 General Filtration Introduction With a focus on sterilizing grade filtration Martha Folmsbee, Pall Life Sciences 10:15 Coffee Break 10:30 Integrity Testing Randy Wilkins, EMD Millipore Magnus Stering, Sartorius-Stedim 11:30 Regulations around Sterile Filtration Vinayak Pawar, FDA 12:00 Lunch Break 13:00 A Basic Microbiological Introduction to Mycoplasma and Bacteria, and How They Differ Barbara Potts, Potts & Nelson Consulting 14:00 Common Sources of Mycoplasma Contamination Helena Windsor, Mycoplasma Experience 14:30 Lessons Learned from an Acholeplasma Laidlawii Contamination in a Biotech Cell Culture Facility Hans Noordergraaf, Abbott 15:00 Coffee Break 15:30 Mycoplasma Filtration Martha Folmsbee, Pall Life Sciences 16:30 Q&A, Panel Discussion with Moderators Martha Folmsbee, Pall Life Sciences Gerhard Haake, Sartorius-Stedim Barbara Potts, Potts & Nelson Consulting 17:00 End of the Course https://europe.pda.org/Myco2014 11 New Flexsafe Bag Family. New PE Film. New Benchmark. Our new Flexsafe bags ensure an excellent and reproducible growth behavior ONE FILM FOR ALL with the most sensitive production cell lines. The optimization of the resin formulation, the complete control of our raw materials, the extrusion process and the bag assembly guarantee a consistent lot-to-lot cell growth performance. USP – DSP – F +F Watch Videos: www.sartorius-stedim.com/flexsafe Floor Plan Wardrobe Life Technologies WC Conference Room WC Sartorius Stedim Greiner Bio-One WC WC Minerva Analytix PDA Registration Buffet/Coffee Station Table Top 3m x 2m (6m2) https://europe.pda.org/Myco2014 13 Exhibitor Abstracts Greiner Bio-One GmbH Maybachstr. 2 72636 Frickenhausen Germany Phone: +49 7022 94 80 Fax: +49 7022 94 85 14 [email protected] www.gbo.com Minerva Analytix GmbH Köpenicker Str. 325 12555 Berlin Germany Tel: +49 30 20 00 43 75 0 Fax: +49 30 20 00 43 75 1 [email protected] www.minerva-analytix.com Greiner Bio-One Diagnostics is a business unit of Greiner Bio-One. Our business focus is the molecular diagnostics of infectious diseases. Our products are distributed worldwide through a specialised sales force and our international dealer network. Our key products are in the fields of a) sexually transmitted infectious diseases (STDs), b) healthcare associated infections (HAIs) and c) products for vaccine safety. We offer our customers complete solutions, from sample withdraw to digital result administration. With our technologies, we cover the high-throughput screening diagnostic market as well as bedside, individualised and easy to use rapid diagnostics for hospitals and medical practices. Minerva Analytix GmbH is a leading analytical, GMP certified service lab for the control of microbial contamination. The company is based in Berlin. The core competence lies in the control of mycoplasma, bacteria and viruses in cell cultures and biopharmaceuticals. The Team of Minerva Analytix includes only high qualifield and trained persons with a deeply understanding of quality and customer satisfaction. The Lab provides specialized service for Research & Development, ATMPs, Pharmaceutical Industries and Media Manufacturer and is readily and economically available worldwide. Life Technologies GmbH Frankfurter Str. 129b 64293 Darmstadt Germany Tel: +49 6151 9670 0 Fax: +49 6151 9670 5259 [email protected] www.lifetechnologies.com Life Technologies™ products harness the power of science to transform lives. As a member of the Thermo Fisher Scientific family of brands, our instruments, everyday tools, and services offer high-quality, innovative life science solutions for every lab and application. Go to lifetechnologies.com to learn more. 14 https://europe.pda.org/Myco2014 Sartorius Stedim Biotech GmbH August Spindler-Str. 11 37079 Göttingen Germany Tel: +49 551 30 80 Fax: +49 551 30 83 28 9 [email protected] www.sartorius.de PREMIUM SPONSOR Sartorius is one of the world's leading providers of laboratory and process technologies and equipment. The Lab Products & Services Division is a premium supplier of highquality laboratory instruments, high-grade consumables and excellent services. Our customers are from the pharmaceutical, chemical and food industries as well as from the academic sector. The product portfolio focuses on high-value laboratory instruments, such as lab balances, pipettes and laboratory water purification systems. Moreover, we offer the widest range of consumables, such as laboratory filters and pipette tips. S ONNENHOF PDA Europe supports the children's hospice „Sonnenhof” The Sonnenhof Hospice, located near PDA’s office in Berlin, offers support and assistance to families with children suffering from incurable and/or debilitating diseases. At Sonnenhof, children, together with their families, can spend the time they have left as they wish and find some relief from their suffering. Instead of purchasing expensive gifts for the conference speakers, PDA has decided to donate this amount to the Sonnenhof Hospice. You can also conS ONNENHOF tribute and help us increase the amount, it is easy: buy a package of chewing gums at the registration desk. THANK YOU! To know more about the Sonnenhof Hospice, please visit www.bjoern-schulz-stiftung.de MYCOPLASMA AND VIRUS TESTING SERVICES FOR BIOLOGICALS S ONNENHOF Contamination of cell cultures with mycoplasmas or viruses can occur in manifold ways regardless the safety standards of the lab. It is important to check cultures in research, development and routine production frequently to minimize the impact of an undetected contamination. In pharmaceutical industry mycoplasma testing is a strictly regulated aspect in product manufacturing. Minerva Analytix offers an expert and reliable service with a broad range of testing procedures for cell cultures and other biological materials. Our testing service for mycoplasmas is based on a European Pharmacopoeia (2.6.7) compliant, validated Real-Time PCR Test system including a turnaround time (sample to result) of <48h. The entire service lab is accredited according to DIN EN ISO 17025 and GMP certified. Intensive audits and long term experiences allow state-of-the-art testing even with complicated sample matrices and for special customer needs. Please contact the Minerva Analytix Team for more detailed information, or visit our homepage. Köpenicker Straße 325 D-12555 Berlin Tel. +49 (0)30 2000 4375-0 Fax +49 (0)30 2000 4375-1 [email protected] www.minerva-analytix.com Connecting People, Science and Regulation® The Parenteral Drug Association presents: 2015 PDA Europe Conference Pharmaceutical Microbiology Current State & Future Focus 18-19 February Conference | Exhibition https://europe.pda.org/Microbio2015 Mark Your Calendar 18-19 February 2015 Hilton Hotel Berlin | Germany